We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Rapid Stool Test Could Help Pinpoint IBD Diagnosis

By LabMedica International staff writers
Posted on 19 Jan 2026

Inflammatory bowel disease (IBD) is a chronic condition in which the immune system mistakenly attacks the digestive tract, causing persistent gut inflammation. More...

Diagnosis and disease monitoring often depend on colonoscopy, an invasive and costly procedure that many patients undergo repeatedly. Existing stool tests measure general inflammation markers and cannot reliably pinpoint whether inflammation originates in the gut. Researchers have now developed a tool that directly detects gut-specific immune activity in fecal samples, offering a more precise and less invasive approach.

In the research led by the University of Edinburgh (Scotland, UK), investigators focused on granzyme A (GzmA), an enzyme released by overactive T cells that are known to drive tissue damage and inflammation in IBD. After identifying elevated GzmA levels in inflamed intestinal tissue from IBD patients, the team designed an optical luminescent reporter that emits light when it detects GzmA activity.

The reporter produces stronger light signals when enzyme activity is higher, allowing inflammation levels to be quantified directly from stool samples. Unlike conventional fecal tests that measure indirect markers such as calprotectin, this approach targets a molecule closely linked to immune-driven gut inflammation. The tool is designed to be fast, sensitive, and compatible with non-invasive stool testing workflows.

The luminescent reporter was tested on 150 stool samples from both IBD patients and healthy individuals. When combined with standard fecal calprotectin testing, the new method identified IBD more accurately than calprotectin alone. The findings, published in the journal Gut, demonstrate that measuring GzmA activity provides additional, disease-relevant information.

Researchers suggest that the ability to detect gut-specific immune activity could reduce unnecessary colonoscopies and enhance diagnostic confidence. The tool could also support personalized treatment by enabling rapid monitoring of inflammation levels in response to therapy. Further validation studies are planned before the approach can be translated into routine clinical use.

“The speed and sensitivity of our optical tool has the potential to accelerate future studies into the roles of the immune system in IBD, as well as improving the pathway to diagnosis,” said Professor Marc Vendrell, study lead. “In the future, these optical tools could also be used to help tailor treatments for IBD patients.”

Related Links:
University of Edinburgh


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
HPV Molecular Test
BD Onclarity HPV Assay
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study validated a genetic scoring tool designed to help physicians diagnose idiopathic pulmonary fibrosis and stratify risk for severe outcomes, including death or lung transplantation (Image Credit: Adobe Stock)

Genetic Risk Score Supports Diagnosis and Prognosis in Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) causes progressive, irreversible lung scarring that limits breathing and can lead to death. More than 100,000 Americans live with IPF, and an estimated 30,000–40,000... Read more

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image

Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms

Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more

Industry

view channel
Im

Eurobio Scientific Completes Acquisition of CareDx Lab Products Division

Eurobio Scientific has closed the acquisition of CareDx AB in Sweden and its fully owned subsidiaries in the United States and Australia that constitute CareDx’s Lab Products division. The business will... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.